TABLE 2.
Results of RVP Testing and Clinical Outcomes in Children With Community-Acquired Pneumonia.
| RVP Negative | RVP Positive
|
|||||
|---|---|---|---|---|---|---|
| All Viruses | RSV | RV/EV | hMPV/PIV/IFV | AdV/CoV/BV | ||
|
|
||||||
| (n = 75) | (n = 127) | (n = 32) | (n = 35) | (n = 32) | (n = 13) | |
| Median age, y (IQR) | 3 (0.3–8) | 1 (0.3–4)a | 1 (0.1–2)a | 3 (0.8–6) | 2 (0.8–4) | 1 (0.3–5) |
| Outcomes | ||||||
| Median LOS, d (IQR) | 3 (2–7) | 4 (2–7) | 6 (4–11)a | 3 (2–5) | 4 (3–9) | 3 (2–6) |
| Respiratory support | 62 (83.8%) | 114 (89.8%) | 31 (96.9%) | 30 (85.7%) | 28 (87.5%) | 12 (92.3%) |
| Median duration of respiratory support, d (IQR) | 2 (1–5) | 3 (2–5)a | 4.5 (3–8)b | 2 (1–4) | 3 (2–5) | 2 (2–4) |
| Intensive care admission | 41 (55.4%) | 81 (63.8%) | 24 (75%)a | 19 (54.3%) | 19 (59.4%) | 9 (69.2%) |
| Invasive mechanical ventilation | 13 (17.6%) | 42 (33.1%)a | 14 (43.8%)b | 7 (20%) | 11 (34.4%) | 4 (30.8%) |
| Parenteral antibiotic therapy | 66 (89.2%) | 122 (96.1%) | 30 (93.8%) | 34 (97.1%) | 30 (93.8%) | 13 (100%) |
| Median duration of parenteral antibiotics, h (IQR) | 65 (37–121) | 62 (40–144) | 72.5 (44–148) | 53 (36–101) | 68 (24–169) | 66 (44–124) |
Respiratory support is defined as any supplemental oxygen or positive pressure ventilation. AdV, adenovirus; BV, bocavirus; CoV, coronavirus; HMpV; human metapneumovirus; IFV, influenza virus; PIV, parainfluenza virus; RV/EV: rhinovirus/enterovirus.
a
P < .05 versus RVP negative.
b
P < .01 versus RVP negative.